logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Data Shows Vaccine Candidate Effective In Dengue Caused By 3 Virus Types

French drugmaker Sanofi's (SNY, SNYNF) vaccines division Sanofi Pasteur late Monday announced the online publication of clinical study results showing that its vaccine candidate protects against dengue fever caused by three dengue virus types.

The results of the world's first efficacy study confirm the safety profile of the dengue vaccine candidate, the firm said. The study results have been published in The Lancet.

Dengue is a mosquito-borne disease caused by four dengue virus serotypes. It is a threat to nearly 3 billion people, especially in some countries of Latin America and Asia.

The full analysis of vaccine efficacy against each serotype, reflecting real-life conditions, showed vaccine efficacy to be 61.2 percent against dengue virus type 1, 81.9 percent against type 3 and 90 percent against type 4.

One of the dengue virus types (serotype 2) eluded the vaccine. Sanofi said analyses are in progress to understand the lack of protection for serotype 2 in the particular epidemiological context of Thailand.

The study was conducted in 4,002 children aged 4 to 11 years, in partnership with the Mahidol University under the patronage of the Thai Ministry of Public Health.

Sanofi Pasteur's dengue vaccine candidate is a live, attenuated vaccine. The vaccination schedule is 3 doses given 6 months apart at 0, 6 and 12 months.

Dr. Scott Halstead, International Vaccine Institute, Seoul, Republic of Korea, said, ''The complexity of dengue virus infection has hampered vaccine research for decades. This is the first time in 50 years of dengue research that I have seen a vaccine that protected a large group of children from clinical disease caused by dengue viruses. Best yet, the vaccine met the highest safety expectations."

Large-scale phase III clinical studies of the dengue vaccine candidate are underway with 31,000 children and adolescents in 10 countries in Asia and Latin 2/3 America. These studies are expected to generate additional data in a broader population and in several epidemiological settings.

Sanofi closed in Paris on Monday lower by 0.65 percent at 65.72 euros on 2.01 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
General Motors (GM) announced on Wednesday that it has been approved to voluntarily delist from the Toronto Stock Exchange. The auto giant reassured its shareholders that the TSX delisting will not impact its current listing on the New York Stock Exchange. Subsequent to the bankruptcy filing of German no frills airline Air Berlin (AIBEF.PK), Lufthansa airline is strongly pursuing to acquire Air Berlin. Meanwhile, Ryanair, its Irish rival, accused conspiracy in the deal and said that the acquisition move will breach the existing competition rules in Germany in general and EU in particular. The Royal Bank of Scotland plans to cut 880 jobs from its IT department in London by 2020, a UK labor union reported. Britain's Unite union claimed on Tuesday that the bank informed its staff about a further 40 percent cut of permanent IT jobs, which is said to be part of ongoing deep cost-cutting at the taxpayer-owned bank. The bank also plans a 65 percent reduction of contractors.
comments powered by Disqus
Follow RTT